Nashville, TN, December 4, 2006 - Preliminary new research discussed today at the American College of Neuropsychopharmacology's Annual Meeting finds that oxytocin, when administered using intravenous fluid and nasal technology may have significant positive effects on adult autism patients. The study, funded by the Seaver Foundation, examined the effects of oxytocin on repetitive behaviors and aspects of social cognition in adults with autism.
Investigators Eric Hollander, MD and Jennifer Bartz, PhD presented results of both intravenous and intranasal administration of oxytocin in high-functioning adult autism patients and discussed the implications of this research for the treatment of autism. Dr. Hollander is Chairman of Psychiatry and at the Mt. Sinai School of Medicine in New York, NY and Director of the Seaver and New York Autism Center of Excellence, one of eight NIH-funded (STAART) centers devoted to the study of autism. Dr. Bartz is a Post Doctoral Fellow at the Seaver Center at the Mt., Sinai School of Medicine.
"Studies with animals have found that oxytocin plays a role in a variety of behaviors, including parent-child and adult-to-adult pair bonding, social memory, social cognition, anxiety reduction and repetitive behaviors," explained Dr. Bartz. "However," adds Dr. Hollander, "we have only recently considered that administration of oxytocin can have behavioral effects. Autism is a particularly ripe neuropsychiatric disorder for studying this approach because it presents with the types of symptoms that have been found to be associated with the oxytocin system."
High-functioning adults with autism or Asperger's disorder received an intravenous infusion of pitocin (synthetic oxytocin) or placebo (saline solution) over a four-hour period. During that time, participants were monitored for repetitive behaviors that are hallmarks of autism spectrum disorders including need to tell/ask, touching, and repeating. These behaviors were assessed at a baseline and throughout the course of the infusion.
"Repetitive behaviors are often overlooked as symptoms of autism in favor of more dramatic symptoms like disrupted social functioning," noted Hollander. "However, early repetitive behavior is often the best predictor of a later autism diagnosis."
The infusion produced results that were both clinically and statistically significant. Hollander noted a rapid reduction of repetitive behaviors over the course of the oxytocin infusion, whereas no such reduction occurred following the placebo infusion, suggesting that oxytocin does indeed address these symptoms.
Researchers also looked at the effects of oxytocin on social cognition. Autism patients are often unable to detect or read emotion in others through facial and voice cues, resulting in the decreased ability to have meaningful interactions with others that characterizes individuals with this disease.
To test participants' ability to assign affective significance to speech, participants listened to pre-recorded sentences with neutral semantic content that were presented with different intonations such as anger, sadness, or happiness. Participants were asked to identify the emotion. Participants received intravenous infusions of pitocin (synthetic oxytocin) or placebo (saline solution) over a four-hour period; participants then returned approximately two weeks later, receiving the alternate compound. Comprehension of affective speech was assessed throughout the four-hour infusion on both occasions, that is, once with intravenous infusion of oxytocin and once without.
Most interestingly, participants who received oxytocin on the first testing day retained the ability to assign affective significance to speech, performing above expectations when they returned approximately two weeks later. This effect was not found among participants who received the placebo on the first testing day.
Hollander and his colleagues are now using nasal technology to study the treatment implications of oxytocin in a controlled six week trial. "The intranasal administration of oxytocin is important because it may allow for better penetration of the blood brain barrier, and is easier to administer," explained Hollander. "When administered orally, oxytocin is metabolized and only a small amount reaches the brain. This is important because the behavioral effects of oxytocin are thought to result from its action on the brain."
Hollander and his colleagues are among the first group to have used intravenous fluid technology and nasal technology to study the behavioral effects of oxytocin in autism spectrum disorders. Though the findings are promising, Hollander cautions that this research is still very preliminary.
"Our findings will need to be replicated in large scale, placebo controlled trials to fully explore treatment potential," said Hollander. "And, though both intravenous and intranasal approaches have been well tolerated, we need to understand more about the safety of these potential treatments, particularly before these effects are explored in autistic children."
ACNP is holding its Annual Meeting December 3 - 7, 2006, in Hollywood, FL.
ACNP, founded in 1961, is a professional organization of more than 700 leading scientists, including three Nobel Laureates. The mission of ACNP is to further research and education in neuropsychopharmacology and related fields in the following ways: promoting the interaction of a broad range of scientific disciplines of brain and behavior in order to advance the understanding of prevention and treatment of disease of the nervous system including psychiatric, neurological, behavioral and addictive disorders; encouraging scientists to enter research careers in fields related to these disorders and their treatment; and ensuring the dissemination of relevant scientific advances. A non-profit organization, ACNP receives revenues from a variety of sources including membership dues, publication sales, registration fees, and pharmaceutical industry grants.